Halozyme Therapeutics Inc. (NASDAQ:HALO) traded up 1.8% during mid-day trading on Thursday . The stock traded as high as $9.17 and last traded at $9.04, with a volume of 492,334 shares traded. The stock had previously closed at $8.88.

Several equities research analysts recently issued reports on the stock. Wells Fargo & Co. restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, May 10th. Canaccord Genuity reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $15.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, June 9th. Jefferies Group reiterated a “sell” rating and set a $6.75 price target on shares of Halozyme Therapeutics in a research note on Tuesday, May 10th. Finally, Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. Halozyme Therapeutics presently has an average rating of “Buy” and a consensus price target of $15.68.

The stock’s market cap is $1.16 billion. The firm’s 50-day moving average price is $9.10 and its 200-day moving average price is $10.00.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04. The firm had revenue of $42.50 million for the quarter, compared to the consensus estimate of $29.65 million. The company’s revenue was up 127.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.12) EPS. On average, equities analysts expect that Halozyme Therapeutics Inc. will post ($1.03) earnings per share for the current year.

A number of hedge funds and institutional investors recently modified their holdings of HALO. Wells Fargo & Company MN raised its position in shares of Halozyme Therapeutics by 1.0% in the fourth quarter. Wells Fargo & Company MN now owns 135,054 shares of the biopharmaceutical company’s stock worth $2,340,000 after buying an additional 1,367 shares during the last quarter. New York State Common Retirement Fund raised its position in shares of Halozyme Therapeutics by 5.4% in the fourth quarter. New York State Common Retirement Fund now owns 372,785 shares of the biopharmaceutical company’s stock worth $6,460,000 after buying an additional 18,940 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Halozyme Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 196,510 shares of the biopharmaceutical company’s stock worth $3,406,000 after buying an additional 3,096 shares during the last quarter. BB Biotech AG raised its position in shares of Halozyme Therapeutics by 1.4% in the fourth quarter. BB Biotech AG now owns 7,029,832 shares of the biopharmaceutical company’s stock worth $121,827,000 after buying an additional 100,000 shares during the last quarter. Finally, NJ State Employees Deferred Compensation Plan raised its position in shares of Halozyme Therapeutics by 480.0% in the fourth quarter. NJ State Employees Deferred Compensation Plan now owns 145,000 shares of the biopharmaceutical company’s stock worth $2,513,000 after buying an additional 120,000 shares during the last quarter.

Halozyme Therapeutics, Inc is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company’s development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.